NYSE: BIOA STOCK INFORMATION

Select from the drop-down menu below to view the latest trading information on our common stock and warrants, which are both traded on the New York Stock Exchange (NYSE:BIOA and NYSE:BIOA.WS respectively).

NYSE: BIOA STOCK INFORMATION

Back to Top

ANALYST COVERAGE

ANALYST COVERAGE
Jeffrey Osborne Cowen & Co. +1 (646) 562-1391
Amit Dayal Rodman & Renshaw +1 (212) 356-0517
Dirk Lever AltaCorp. +1 (403) 539-8606
Back to Top

SEC FILINGS

SEC FILINGS

View all SEC filings

 

 

Loading data...
Back to Top

CORPORATE PRESENTATIONS

CORPORATE PRESENTATIONS
BioAmber Corporate Video
BioAmber Sarnia Plant Slideshow
Download Transcript of Earnings Call Webcast
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
prev prev
Back to Top

LEADERSHIP & GOVERNANCE

LEADERSHIP & GOVERNANCE

BioAmber has assembled a team of industry veterans in the fields of industrial biotechnology and chemicals. Having assembled unmatched experience and unrivalled technical and business acumen, BioAmber is positioned to lead the emergence of economically-viable, sustainable chemicals. The company has staffed its board of directors and management team with seasoned professionals possessing strong track records and complementary experience.

Directors

Raymond J. Land Chairman
 
Kurt Briner
 
Rick Eno
 
Robert Frost
 
Heinz Haller
 
Ellen B. Richstone
 
Kenneth W. Wall
 

Senior Management

Rick Eno
 
R. Laurent Bernier
 
Thomas Desbiens
 
Mike Hartmann
 
James Millis
 
Fabrice Orecchioni
 
Mario Settino

Board Committees

The management team is to promote sustainable development, ownership of issues, proper behavior, and innovative technology, all of which foster eco efficiency and a safe working environment. We are firmly committed to the pursuit of HSE excellence – not just for today but for the future.

The Company’s Board of Directors has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee, each of which operates pursuant to a charter adopted by our board of directors.

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.

  Audit Committee Compensation Committee Nominating and Corporate Governance Committee
Kurt Briner     chair
Heinz Haller     member
Ellen B. Richstone chair member  
Kenneth W. Wall member member  
Robert Frost member    
Raymond J. Land   chair member
Board Committees & Governance

Back to Top

Previous
  • Raymond J. Land

    Raymond J. Land

    Chairman, Interim-CFO and Interim-Corporate Secretary

    Raymond J. Land has served on our Board since 2011 and has been the Chairman of our Board since February 2012. Mr. Land retired after most recently serving as the Senior Vice President and CFO of Clarient, Inc., a cancer diagnostics company, where he worked from 2008 until his retirement. From 2007 to 2008, he was the Senior Vice President and CFO of Safeguard Scientifics, Inc., a venture capital firm. In 2006, Mr. Land was Executive Vice President and CFO of Medcenter Solutions, Inc., a medical education and marketing services company in the pharmaceuticals industry, and from 2005 to 2006, he was Senior Vice President and CFO of Orchid Cellmark Inc., a DNA testing company. Mr. Land also served as Senior Vice President and CFO for Genencor International, Inc., from 1997 until its acquisition in 2005. From 1991 to 1996, he served as Senior Vice President and CFO for West Pharmaceutical Services, Inc. Previously, Mr. Land has also held various positions at Campbell Soup Company, Inc. and at Coopers & Lybrand, an accounting firm. Mr. Land currently serves on the board of directors of Anika Therapeutics, Inc., where he is the chair of the audit committee, and Mountain View Pharmaceuticals, Inc., a privately held pharmaceuticals company. Mr. Land is a Certified Public Accountant (Retired) and received a Bachelor of Business Administration in accounting and finance from Temple University. Mr. Land’s service on the boards of directors and leadership positions at numerous companies in the biotechnology and pharmaceutical industries make him a valuable member of our Board. 

  • Kurt Briner

    Kurt Briner

     

    Kurt Briner has served on our Board since 2009 and was Chairman of our Board from 2009 to February 2012. Mr. Briner was President and CEO of Sanofi Pharma S.A. from 1988 until his retirement in 1998 and has since been an independent consultant to pharmaceutical and biotechnology companies. He has over 35 years of experience in the pharmaceutical industry and was a member of the board of directors of Novo Nordisk, Progenics Pharmaceuticals Inc., and Galenica S.A., a European-based pharmaceutical company. Mr. Briner received a Diploma from École de Commerce in Basel and Lausanne. Mr. Briner’s extensive experience in the pharmaceutical and biotechnology industries, his service in senior management and as a board member of large business enterprises and appreciation of business organizations and practices in diverse international cultures add to his many qualifications as a director. 

  • Rick Eno

    Rick Eno

    Chief Executive Officer
    Mr. Eno joined BioAmber as CEO in September 2017. Rick has over 30 years of related management experience in the energy, chemicals, biotechnology and materials industries. He began his career in Chevron's chemical operations with roles of increasing responsibility in engineering, manufacturing and construction operations. He then entered management consulting where he worked with chemical and energy clients around the world on key strategic and operational issues. In 2008, Rick became President, CEO and Board member at Metabolix, a publicly traded industrial biotechnology company focused on commercializing a family of bio-based, biodegradable polymers. Most recently, he was a senior partner at Roland Berger, and international management consultancy. Rick has a B.S. in Chemical Engineering degree from Cornell University, a Masters in Business Administration from the University of Houston and is a Chartered Financial Analyst (CFA).
  • Robert Frost

    Robert Frost

     

    Since 2009, Mr. Frost has been an independent advisor to many businesses including Naxos Capital Partners, an investor in BioAmber, and has acted in this capacity on the boards of listed and private companies in Europe and private companies in the US.

    Prior to this, Mr. Frost was a Managing Director with Allianz Capital Partners, responsible for activities in their private equity, mezzanine and infrastructure portfolios. During this time he served on the boards of multiple companies and was responsible for more than $2bn of equity capital invested on behalf of the Allianz group. Previously Mr. Frost also held senior positions in the Nikko and Nomura Principal Finance Groups in London.

    Mr. Frost holds an M.B.A. from the London Business School.

  • Heinz Haller

    Heinz Haller

    Executive

    Heinz Haller has served on our Board since 2011. He is Executive Vice President and President of Europe, Middle East, Africa and India of Dow Europe GmbH. He has worked at Dow in various roles from 2006 through the present, from 1987 to 1994 and from 1980 to 1985. From 2002 to 2006, Mr. Haller served as Managing Director of Allianz Capital Partners, GmbH, a private equity firm. Prior to that, he was CEO of both Red Bull Sauber AG, a company that provides automotive research and development services and Sauber Petronas Engineering AG. He has also worked as Managing Director of Plüss-Staufer AG, a chemical distribution company. Mr. Haller is Chairman of the Dow Kokam Board and the Dow AgroSciences Members Committee, as well as a member of the Board of Directors for the Dow Corning Corporation, the Michigan Molecular Institute, and the U.S. India Business Council. Mr. Haller earned a certification in the advanced executive program from University of California at Los Angeles and holds a Master of Business Administration from IMD, Lausanne, Switzerland. His experience in leadership roles and knowledge of the chemical industry makes him a valuable member of our Board.

  • Ellen B. Richstone

    Ellen B. Richstone

    Executive

    Ms. Ellen B. Richstone was the CFO of several public and private companies between 1989 and 2012, including Rohr Aerospace (a Fortune 500 Company) and Executive VP of Darwin Scientific between June 2011 and September 2012. From 2002 to 2004, Ms. Richstone was the President and CEO of the Entrepreneurial Resources Group. From 2004 until its sale in 2007, Ms. Richstone served as the financial expert on the board of directors of American Power Conversion. Ms. Richstone currently serves on the boards of two other public companies: eMagin Corporation (NYSE: EMAN) and Superior Industries International Inc. (NYSE: SUP). She has prior experience on both public and private boards and her current private boards include the National Association of Corporate Directors-New England. She chairs the Audit Committees of both eMagin and Parnell Pharmaceuticals Inc. In April 2013, Ms. Richstone was given the first annual Distinguished Director Award from the Corporate Directors Group. Ms. Richstone graduated from Scripps College in Claremont California and holds graduate degrees from the Fletcher School of Law and Diplomacy at Tufts University. Ms. Richstone also completed the Advanced Professional Certificate in Finance at New York University’s Graduate School of Business Administration and attended the Executive Development program at Cornell University’s Business School. Ms. Richstone holds an Executive Master’s Certification in Director Governance from the American College of Corporate Directors. We believe that Ms. Richstone’s broad industry experience in technology, industrial and cleantech along with her financial expertise and extensive governance experience makes her a valuable member of our Board.

  • Kenneth W. Wall

    Kenneth W. Wall

     

    Kenneth W. Wall has served on our Board since August 2013. Mr. Wall previously served as BioAmber’s Chief Operations Officer from October 2012 to June 2013. From 2011 to October 2012, Mr. Wall served as our Senior Vice President of Manufacturing. From 2005 to 2011, Mr. Wall was a consultant to the chemical industry. In 2004, Mr. Wall was President of Intermediates and Specialty Products business at INVISTA. Prior to 2004, Mr. Wall served in various positions at DuPont since 1974 and culminating as Vice President and General Manager of DuPont’s Nylon Intermediates, Polymers and Specialties division. Mr. Wall’s broad experience includes roles such as Director of Integrated Operations, Director of Manufacturing, Global Business Manager, Plant Superintendent, R&D Director, Product Manager and Staff Engineer. Mr. Wall holds a Ph.D. in chemical engineering from the University of Missouri-Rolla, a Master of Science in chemical engineering from the University of Missouri-Rolla and a Bachelor of Science in chemical engineering from the University of Missouri-Rolla. Mr. Wall’s extensive knowledge of the company and his over 39 years of experience working for and knowledge of the chemical industry makes him a valuable member of our Board.

Next
Previous
  • Rick Eno

    Rick Eno

    CEO
    Mr. Eno joined BioAmber as CEO in September 2017. Rick has over 30 years of related management experience in the energy, chemicals, biotechnology and materials industries. He began his career in Chevron's chemical operations with roles of increasing responsibility in engineering, manufacturing and construction operations. He then entered management consulting where he worked with chemical and energy clients around the world on key strategic and operational issues. In 2008, Rick became President, CEO and Board member at Metabolix, a publicly traded industrial biotechnology company focused on commercializing a family of bio-based, biodegradable polymers. Most recently, he was a senior partner at Roland Berger, and international management consultancy. Rick has a B.S. in Chemical Engineering degree from Cornell University, a Masters in Business Administration from the University of Houston and is a Chartered Financial Analyst (CFA).
  • R. Laurent Bernier

    R. Laurent Bernier

    Senior VP

    Laurent Bernier has served in several capacities since joining BioAmber in 2008. Prior to joining BioAmber, Dr. Bernier was Vice President Eastern Canada for Foragen Technology Management Inc., a venture capital fund created to help commercialize early-stage, advanced agricultural technologies from Canadian sources. Before Foragen, he was the founding Executive Director of BioNB (formerly known as BioAtlantech), New-Brunswick’s lead agency for the development of the bio-industries and had been previously Vice President Life Sciences for Inno-centre, a Montreal-based organization dedicated to helping advanced technology entrepreneurs start up commercial ventures. As an industrial researcher, Laurent Bernier has held various research and managerial positions at C-I-L, ICI Canada and Zeneca BioProducts, where he directly contributed to the discovery, development and launch of five biotechnology-related products and services. He is listed as an inventor of a dozen biotechnology related patents and has published extensively in the area of agricultural and forestry biotechnology. He received his Ph.D. in Microbiology and Immunology from the University of Montreal. He was a recipient of an INSERC industrial post-doctoral fellowship conducted at FPInnnovations (formerly the Pulp and Paper Research Institute of Canada or PAPRICAN) in collaboration with McGill University in Montreal. He is currently Chairman of the Board of CRIBIQ (QC) and AIREX Énergie inc.

  • Thomas Desbiens

    Thomas Desbiens

    General Counsel

    Thomas Desbiens is a business and intellectual property lawyer with more than twenty years of experience as partner in a boutique law firm, who oversees BioAmber’s legal matters, including its corporate & commercial transactions, financing activities, strategic partnerships and securities compliance & corporate governance matters.

  • Mike Hartmann

    Mike Hartmann

    President of BioAmber Sarnia Inc.

    Michael A. Hartmann is currently President of BioAmber Sarnia, previously serving as our Executive Vice President since 2009. From 1998 to 2008, Mr. Hartmann was an Executive Director of Institutional Sales at CIBC World Markets Inc. Prior to that, Mr. Hartmann had business and sales roles at Sprott Securities, Dlouhy Investments Inc. and Thomson Kernaghan & Co. Ltd. Mr. Hartmann received an International Master of Business Administration from York University in Toronto and a Bachelor of Arts from Rollins College.

  • James Millis

    James Millis

    CTO

    James Millis has served as our Chief Technology Officer since 2009. Prior to joining the company, Mr. Millis served as CEO of Draths Corporation, a chemical company that focused on manufacturing bio-based materials, from 2007 to 2009. From 2001 to 2007, he served as Technical Director for Cargill’s Industrial Bioproducts business unit. Earlier positions included business and technical leadership roles at Maxygen Inc. and Bio-Technical Resources. Mr. Millis has been involved in the commercial development and scale-up of several technologies, spanning fermentation and chemical catalysis, and is co-inventor on 25 U.S. patents and their foreign equivalents. Mr. Millis holds a Master of Science in chemical engineering from the University of Pittsburgh and a Bachelor of Science in chemical engineering from Cornell University.

  • Fabrice Orecchioni

    Fabrice Orecchioni

    President & COO

    Currently President and COO of BioAmber, Fabrice Orecchioni managed the engineering, construction, commissioning and subsequent operations of the largest Succinic Acid plant in the world. After joining BioAmber in 2012 to manage the demonstration plant in France, Fabrice was involved in the design of the commercial scale bio-succinic plant in Sarnia, Ontario. This first of a kind 30,000 ton facility was completed and commissioned in 2015. Since inception,  Fabrice served as President of the BioAmber Sarnia joint venture with Mitsui & co., where he managed day to day operations and coordinated global marketing with Mitsui & co. Prior to joining BioAmber, Fabrice spent 10 years in process engineering and operations with Tate and Lyle and Ajinomoto in the Amino Acids business, and spent 5 years as the Operations and Plant Manager at the French bioethanol asset of Abengoa Bioenergy. Fabrice holds an Executive Master of Business Administration from HEC Paris, an engineering degree in industrial processes from Ecole de Biologie Industrielle and a degree in chemistry from Universite Pierre et Marie -Curie.

  • Mario Settino

    Mario Settino

    CFO
    Mr. Settino joined BioAmber in May 2017. He is a seasoned professional with over 30 years of financial and operational experience in various industries such as services, retail, manufacturing and high-end technology. He previously served as President & CFO of Peds Legwear and prior to this was Chief Financial Officer of Miranda Technologies. Mr. Settino has previously held senior financial positions with Loblaws, Bombardier and LGS, (an IBM company). He is a chartered professional accountant who began his career at Deloitte and holds a bachelor of commerce degree from Concordia University and a graduate diploma in accountancy from McGill University.
Next

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008

2016 Archives

Dec 23, 2016

BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced that it has priced an underwritten offering of 1,748,750 shares of its common stock at a price of $4.00 per share. The...

More
Dec 19, 2016

Intent is to produce cost competitive bio-succinic acid in China to accelerate sales growth MONTREAL, Dec. 19, 2016 /CNW Telbec/ - BioAmber Inc. (NYSE: BIOA) has signed a non-binding letter of...

More
Nov 3, 2016

BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced financial and operational results for the three months ending September 30, 2016. Highlights Q3 2016 Sales of...

More
Oct 24, 2016

BioAmber Inc. (NYSE:BIOA) today announced that it will report financial results for the third quarter 2016 on Thursday, November 3, 2016 after the close of the market. The company has scheduled a...

More
Sep 21, 2016

If approved, the $360 million loan guarantee will be used to fund BioAmber's next plant MINNEAPOLIS, Sept. 21, 2016 /CNW Telbec/ - BioAmber Inc. (NYSE: BIOA) is pleased to announce an important...

More
Sep 12, 2016

BioAmber Inc. (NYSE: BIOA), is pleased to announce that it has closed on a $19.2 million (CDN $25 million) loan from Bridging Finance Inc., acting as sub-advisor to the Sprott Bridging Income Fund...

More
Aug 30, 2016

BioAmber Inc. (NYSE: BIOA) announced today that its joint venture with Mitsui & Co. has achieved the final operational milestone set out in a CAD$20 million commercial loan that the joint venture...

More
Aug 9, 2016

BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced operational and financial results for the three months ending June 30, 2016. "BioAmber continues to meet ramp-up...

More
Jul 29, 2016

BioAmber Inc. (NYSE: BIOA) today announced that it will report financial results for the second quarter 2016 on Tuesday, August 9, 2016 after the close of the market. The company has scheduled a...

More
May 3, 2016

BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced operational and financial results for the three months ended March 31, 2016. Highlights included: Production in the...

More
Apr 27, 2016

BioAmber Inc. (NYSE: BIOA) today announced that it will report financial results for the first quarter 2016 on Tuesday, May 3, 2016 after the close of the market. The company has scheduled a...

More
Apr 26, 2016

BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced that its Canadian subsidiary BioAmber Sarnia Inc., a joint venture with Mitsui & Co., has secured a CAD$10 million loan...

More
Mar 14, 2016

BioAmber Inc. (NYSE: BIOA), a leader in renewable materials announced operational and financial results for the three months and year ended December 31, 2015. The highlights included: Sales of...

More
Feb 24, 2016

BioAmber Inc. (NYSE:BIOA) today announced that it will report financial results for the fourth quarter 2015 and the full year of fiscal year 2015 on Monday, March 14, 2016 after the close of the...

More
Feb 22, 2016

BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced that George F.J. Gosbee is joining its board of directors, effective today. Mr. Gosbee will replace Henry "Pete"...

More
Feb 10, 2016

BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, is pleased to announce that Mitsui & Co. Ltd., its partner in the Sarnia bio-based succinic acid plant, is investing an additional...

More
Jan 15, 2016

In the news release, BioAmber inc. announces pricing of $11.0 million public offering, issued 15-Jan-2016 by BioAmber Canada Inc. over CNW, we are advised by the company that the title should read...

More
Jan 14, 2016

BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced that it has commenced an underwritten public offering of its common stock. In addition, BioAmber expects to grant the...

More
Jan 14, 2016

BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, announced today that its Sarnia production plant, jointly owned with Mitsui & Co., has received ISO 9001, ISO 14001, OHSAS 18001 and...

More
 

print email rss

CALENDAR & EVENTS

CALENDAR & EVENTS
Wednesday, February 8, 2017
11:30am - 12:30pm EST
Wednesday, April 6, 2016 - Thursday, April 7, 2016
Wednesday, March 16, 2016 - Thursday, March 17, 2016
Monday, March 14, 2016 - Thursday, March 17, 2016
Tuesday, March 8, 2016 - Thursday, March 10, 2016
Back to Top

VISION FOR GROWTH

VISION FOR GROWTH

Accelerating the global adoption of green chemicals

Our Strategic Priorities
  • Rapidly Expand Global Manufacturing Capacity
  • Target the Large and Established 1,4 Butanediol Market
  • Develop Next-Generation Succinic-Derived Products
  • Reduce Production Costs (Continuous Improvement)
  • Expand Product Portfolio to Additional Building Block Chemicals
Back to Top